Cargando…

Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D(3) combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal

BACKGROUND: Vitamin D (VD) insufficiency or deficiency is a frequent comorbidity in Chinese women with postmenopausal osteoporosis (PMO). The present study aimed to investigate 25-hydroxyvitamin D [25(OH) D] improvement and calcium-phosphate metabolism in Chinese PMO patients treated with 70 mg of a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Er-Yuan, Zhang, Zhen-Lin, Xia, Wei-Bo, Lin, Hua, Cheng, Qun, Wang, Li, Hao, Yong-Qiang, Chen, De-Cai, Tang, Hai, Peng, Yong-De, You, Li, He, Liang, Hu, Zhao-Heng, Song, Chun-Li, Wei, Fang, Wang, Jue, Zhang, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030763/ https://www.ncbi.nlm.nih.gov/pubmed/29970059 http://dx.doi.org/10.1186/s12891-018-2090-y

Ejemplares similares

Calcifediol Is Not Superior to Cholecalciferol in Improving Vitamin D Status in Postmenopausal Women
por: Sosa‐Henríquez, Manuel, et al.
Publicado: (2022)

Alendronate improves QOL of postmenopausal women with osteoporosis
por: Kawate, Hisaya, et al.
Publicado: (2010)

LBSAT229 Extended-release Calcifediol Effectively Raised 25-hydroxyvitamin D In CKD Despite Obesity
por: Strugnell, Stephen A, et al.
Publicado: (2022)

Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study
por: Li, Mei, et al.
Publicado: (2022)

Vitamin D Boosts Alendronate Tail Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis
por: Catalano, Antonino, et al.
Publicado: (2021)

The Relationship Between Serum 25-Hydroxyvitamin D Levels and Osteoporosis in Postmenopausal Women
por: Wang, Dongmei, et al.
Publicado: (2023)

Cholecalciferol or Calcifediol in the Management of Vitamin D Deficiency
por: Sosa Henríquez, Manuel, et al.
Publicado: (2020)

Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial
por: Pérez‐Castrillón, José Luis, et al.
Publicado: (2021)

Seven years’ experience with alendronate in postmenopausal Japanese women with osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2010)

Hypovitaminosis D: Is It Time to Consider the Use of Calcifediol?
por: Cesareo, Roberto, et al.
Publicado: (2019)

Calcifediol Cornerstone of the Vitamin D Endocrine System
por: Quesada-Gomez, Jose Manuel, et al.
Publicado: (2023)

Serum 25-hydroxyvitamin D and bone turnover markers in Palestinian postmenopausal osteoporosis and normal women
por: Kharroubi, Akram, et al.
Publicado: (2017)

Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China
por: Liao, Er-Yuan, et al.
Publicado: (2018)

Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend
por: Greenspan, Susan L., et al.
Publicado: (2020)

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
por: Leder, Benjamin Z, et al.
Publicado: (2019)

Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine
por: Radwan, Asma, et al.
Publicado: (2022)

Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials
por: Wang, Ya-Kang, et al.
Publicado: (2017)

Relationship between 25-Hydroxyvitamin D and Newly Diagnosed Type 2 Diabetes Mellitus in Postmenopausal Women with Osteoporosis
por: Vujosevic, Snezana, et al.
Publicado: (2014)

Calcitriol/calcifediol ratio: An indicator of vitamin D hydroxylation efficiency?
por: Pasquali, Marzia, et al.
Publicado: (2015)

25(OH)Vitamin D Deficiency and Calcifediol Treatment in Pediatrics
por: Castano, Luis, et al.
Publicado: (2022)

Vitamin D Endocrine System and COVID-19: Treatment with Calcifediol
por: Quesada-Gomez, Jose Manuel, et al.
Publicado: (2022)

Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature
por: Iwamoto, Jun, et al.
Publicado: (2008)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
por: Bone, Henry G, et al.
Publicado: (2018)

ERRATUM for “Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis”
Publicado: (2020)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Extended-Release Calcifediol Effectively Raises Serum Total 25-Hydroxyvitamin D Even in Overweight Nondialysis Chronic Kidney Disease Patients with Secondary Hyperparathyroidism
por: Bishop, Charles W., et al.
Publicado: (2022)

Efficacy and safety of recombinant human parathyroid hormone (1–34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis
por: Deng, Jing, et al.
Publicado: (2018)

Alendronate Sodium in the Management of Osteoporosis
por: Prinsloo, P J J, et al.
Publicado: (2006)

Calcifediol: Mechanisms of Action
por: Donati, Simone, et al.
Publicado: (2023)

Vitamin D Deficiency in COVID-19 Patients and Role of Calcifediol Supplementation
por: Mingiano, Christian, et al.
Publicado: (2023)

Efficacy of a Once-Monthly Pill Containing Ibandronate and Cholecalciferol on the Levels of 25-Hydroxyvitamin D and Bone Markers in Postmenopausal Women with Osteoporosis
por: Cho, In-Jin, et al.
Publicado: (2015)

The Carcinogenicity of Alendronate in Patients with Osteoporosis: Evidence from Cohort Studies
por: Chen, Ling-Xiao, et al.
Publicado: (2015)

Vitamin D Repletion in Korean Postmenopausal Women with Osteoporosis
por: Chung, Yoon-Sok, et al.
Publicado: (2016)

SUN-386 Treatment Outcomes of Intravenous Zoledronic Acid vs Oral Alendronate in Postmenopausal Women with Osteoporosis
por: Pyone, Zar Chi, et al.
Publicado: (2020)

Economic Evaluation of Oral Alendronate Therapy for Osteoporosis in Chinese Postmenopausal Women: The Impact of Medication Compliance and Persistence
por: You, Ruxu, et al.
Publicado: (2020)

Mechanistic PK-PD model of alendronate treatment of postmenopausal osteoporosis predicts bone site-specific response
por: Calvo-Gallego, José L., et al.
Publicado: (2022)

Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study
por: Villagómez Vega, Alejandra, et al.
Publicado: (2023)

Treatment of Vitamin D Deficiency with Calcifediol: Efficacy and Safety Profile and Predictability of Efficacy
por: Pérez-Castrillon, Jose-Luis, et al.
Publicado: (2022)

Bioconversion of vitamin D(3) to bioactive calcifediol and calcitriol as high-value compounds
por: Wang, Zheyi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t3hcc53ij84epc5a4r7b9fg1p2